X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-18 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $198.75 | -4,570 | 301,319 | -1% | -$908,301 | |||||
2026-03-18 | GH | Guardant Health, Inc. | Tariq Musa | Dir | S - Sale | $88.09 | -348 | 8,394 | -4% | -$30,655 | ||||||
| M | 2026-03-17 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $25.91 | -19,300 | 279,215 | -6% | -$500,098 | |||||
2026-03-13 | NTRA | Natera, Inc. | Chapman Rowan E | Dir | S - Sale | $191.38 | -122 | 5,752 | -2% | -$23,348 | ||||||
| D | 2026-03-16 | GH | Guardant Health, Inc. | Bell Michael Brian | CFO | S - Sale+OE | $87.04 | -3,000 | 43,601 | -6% | -$261,111 | |||||
| M | 2026-03-13 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $25.75 | -30,779 | 298,515 | -9% | -$792,410 | |||||
| D | 2026-03-16 | FTRE | Fortrea Holdings Inc. | Morais Mark A. | COO | S - Sale+OE | $9.22 | -1,804 | 74,524 | -2% | -$16,633 | |||||
| D | 2026-03-16 | FTRE | Fortrea Holdings Inc. | McConnell Jill G. | CFO | S - Sale+OE | $9.22 | -1,804 | 72,276 | -2% | -$16,633 | |||||
| DM | 2026-03-12 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale+OE | $191.42 | -200,000 | 2,315,772 | -8% | -$38,283,382 | |||||
2026-03-12 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $25.24 | -20,863 | 86,825 | -19% | -$526,582 | ||||||
| DM | 2026-03-11 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $25.67 | -44,125 | 329,294 | -12% | -$1,132,821 | |||||
| M | 2026-03-10 | SERA | Sera Prognostics, Inc. | Lindgardt Zhenya | CEO | S - Sale | $1.92 | -25,612 | 738,314 | -3% | -$49,079 | |||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Kearney Paul | Chief Data Officer | S - Sale | $2.04 | -1,396 | 163,961 | -1% | -$2,848 | ||||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Jackson Benjamin | GC | S - Sale | $2.04 | -1,027 | 114,720 | -1% | -$2,095 | ||||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Harrison Robert Gardner | CIO | S - Sale | $2.04 | -716 | 76,712 | -1% | -$1,461 | ||||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Boniface John J. | Chief Scientific Officer | S - Sale | $2.04 | -1,517 | 145,842 | -1% | -$3,095 | ||||||
| M | 2026-03-10 | SERA | Sera Prognostics, Inc. | Aerts Austin | CFO | S - Sale | $1.92 | -7,088 | 264,452 | -3% | -$13,610 | |||||
2026-03-10 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $204.13 | -785 | 63,354 | -1% | -$160,244 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $204.13 | -5,623 | 156,607 | -3% | -$1,147,838 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $204.13 | -1,745 | 233,285 | -1% | -$356,212 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $204.13 | -127 | 305,889 | 0% | -$25,925 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $204.13 | -707 | 189,199 | 0% | -$144,322 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $204.13 | -915 | 150,882 | -1% | -$186,781 | ||||||
| D | 2026-03-10 | FTRE | Fortrea Holdings Inc. | Parks Robert | Chief Accounting Officer | S - Sale+OE | $9.07 | -1,927 | 22,389 | -8% | -$17,478 | |||||
| D | 2026-03-10 | FTRE | Fortrea Holdings Inc. | Morais Mark A. | COO | S - Sale+OE | $9.07 | -4,599 | 72,044 | -6% | -$41,713 | |||||
| D | 2026-03-10 | FTRE | Fortrea Holdings Inc. | McConnell Jill G. | CFO | S - Sale+OE | $9.07 | -5,061 | 69,796 | -7% | -$45,903 | |||||
| D | 2026-03-06 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale+OE | $196.08 | -8,398 | 233,285 | -3% | -$1,646,696 | |||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Kearney Paul | Chief Data Officer | S - Sale | $1.96 | -2,026 | 165,357 | -1% | -$3,971 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Jackson Benjamin | GC | S - Sale | $1.96 | -3,119 | 115,747 | -3% | -$6,113 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Harrison Robert Gardner | CIO | S - Sale | $1.96 | -3,360 | 77,428 | -4% | -$6,586 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Boniface John J. | Chief Scientific Officer | S - Sale | $1.96 | -3,038 | 147,359 | -2% | -$5,954 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Aerts Austin | CFO | S - Sale | $1.96 | -674 | 271,540 | 0% | -$1,321 | ||||||
| M | 2026-03-05 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $48.96 | -3,147 | 306,475 | -1% | -$154,062 | |||||
| M | 2026-03-05 | GRAL | Grail, Inc. | Ofman Joshua J. | Pres | S - Sale | $48.86 | -3,627 | 432,881 | -1% | -$177,227 | |||||
| M | 2026-03-05 | GRAL | Grail, Inc. | Ragusa Robert P | CEO | S - Sale | $48.48 | -8,441 | 642,084 | -1% | -$409,246 | |||||
| D | 2026-03-06 | GH | Guardant Health, Inc. | Hidalgo Medina Manuel | Dir | S - Sale+OE | $91.54 | -1,300 | 1,193 | -52% | -$118,997 | |||||
2026-03-05 | CSTL | Castle Biosciences Inc | Stokes Frank | CFO | S - Sale | $27.98 | -6,001 | 60,085 | -9% | -$167,908 | ||||||
| D | 2026-03-05 | CSTL | Castle Biosciences Inc | Cole G Bradley | Dir | S - Sale+OE | $28.47 | -7,403 | 19,309 | -28% | -$210,727 | |||||
2026-03-06 | SERA | Sera Prognostics, Inc. | Lawrence Sandra Aj | Dir | S - Sale | $1.95 | -1,560 | 18,033 | -8% | -$3,042 | ||||||
2026-03-05 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $206.21 | -5,558 | 71,624 | -7% | -$1,146,115 | ||||||
2026-03-05 | DGX | Quest Diagnostics Inc | Prevoznik Michael E | SVP, GC | S - Sale | $206.21 | -3,878 | 43,294 | -8% | -$799,682 | ||||||
2026-03-05 | DGX | Quest Diagnostics Inc | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $206.21 | -2,855 | 15,198 | -16% | -$588,730 | ||||||
2026-03-04 | DGX | Quest Diagnostics Inc | Kuppusamy Karthik | SVP, Clinical Solutions | S - Sale | $204.86 | -2,628 | 15,457 | -15% | -$538,372 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | Chambers Rebecca | CFO | S - Sale | $36.14 | -18,341 | 131,196 | -12% | -$662,869 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | Stapley Marc | CEO | S - Sale | $35.97 | -45,523 | 357,554 | -11% | -$1,637,594 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | Leite John | Chief Commercial Officer-CLIA | S - Sale | $35.19 | -5,260 | 107,580 | -5% | -$185,083 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | McGuire Annie | SVP, GC | S - Sale | $35.55 | -6,658 | 94,706 | -7% | -$236,725 | ||||||
| D | 2026-03-04 | GH | Guardant Health, Inc. | Kalia Kumud | CIO | S - Sale+OE | $95.32 | -40,000 | 37,643 | -52% | -$3,812,661 | |||||
| D | 2026-03-03 | CSTL | Castle Biosciences Inc | Stokes Frank | CFO | S - Sale+OE | $27.44 | -7,000 | 66,086 | -10% | -$192,073 | |||||
2026-03-03 | LH | Labcorp Holdings Inc. | Schechter Adam H | Pres, CEO | S - Sale | $279.96 | -8,705 | 80,773 | -10% | -$2,437,047 | ||||||
2026-03-03 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $207.73 | -632 | 71,624 | -1% | -$131,285 | ||||||
2026-03-03 | DGX | Quest Diagnostics Inc | Prevoznik Michael E | SVP, GC | S - Sale | $207.73 | -526 | 43,294 | -1% | -$109,266 | ||||||
2026-03-02 | DGX | Quest Diagnostics Inc | Davis J. E. | CEO, Pres | S - Sale | $212.52 | -10,000 | 117,185 | -8% | -$2,125,200 | ||||||
2026-03-03 | DGX | Quest Diagnostics Inc | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $207.73 | -410 | 15,198 | -3% | -$85,169 | ||||||
2026-03-02 | VCYT | Veracyte, Inc. | Febbo Phillip G. | Chief Scientific, Med Officer | S - Sale | $36.16 | -13,425 | 117,346 | -10% | -$485,429 | ||||||
2026-03-03 | XGN | Exagen Inc. | Aballi John | Pres, CEO | S - Sale | $3.62 | -15,698 | 730,235 | -2% | -$56,827 | ||||||
2026-03-02 | GRAL | Grail, Inc. | Ofman Joshua J. | Pres | S - Sale | $50.16 | -17,002 | 436,508 | -4% | -$852,848 | ||||||
2026-03-02 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $200.23 | -3,070 | 305,758 | -1% | -$614,710 | ||||||
2026-03-02 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $200.02 | -3,950 | 156,607 | -2% | -$790,095 | ||||||
| D | 2026-03-02 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale+OE | $199.85 | -3,000 | 150,023 | -2% | -$599,545 | |||||
2026-03-02 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $50.17 | -9,573 | 309,622 | -3% | -$480,244 | ||||||
2026-03-02 | GRAL | Grail, Inc. | Ragusa Robert P | CEO | S - Sale | $50.17 | -37,504 | 650,525 | -5% | -$1,881,417 | ||||||
2026-02-27 | LH | Labcorp Holdings Inc. | Van Der Vaart Sandra D | EVP, Corporate Affairs | S - Sale | $284.91 | -548 | 2,579 | -18% | -$156,000 | ||||||
2026-02-24 | LH | Labcorp Holdings Inc. | Caveney Brian J | EVP, Pres of ED, CMO, CSO | S - Sale | $286.31 | -1,500 | 30,107 | -5% | -$429,458 | ||||||
2026-02-24 | XGN | Exagen Inc. | Aballi John | Pres, CEO | S - Sale | $3.61 | -11,430 | 743,398 | -2% | -$41,262 | ||||||
2026-02-24 | XGN | Exagen Inc. | Black Jeffrey G. | CFO | S - Sale | $3.61 | -1,584 | 267,442 | -1% | -$5,718 | ||||||
2026-02-24 | SERA | Sera Prognostics, Inc. | Harrison Robert Gardner | CIO | S - Sale | $2.34 | -2,000 | 80,788 | -2% | -$4,680 | ||||||
| D | 2026-02-23 | BDSX | Biodesix Inc | Pestano Gary Anthony | Chief Development Officer | S - Sale+OE | $12.78 | -556 | 10,359 | -5% | -$7,103 | |||||
| D | 2026-02-23 | BDSX | Biodesix Inc | O'Kane Kieran | Chief Commercial Officer | S - Sale+OE | $12.78 | -535 | 9,819 | -5% | -$6,835 | |||||
| D | 2026-02-23 | BDSX | Biodesix Inc | Cowie Robin Harper | CFO, Sec'y, Treasurer | S - Sale+OE | $12.78 | -535 | 16,231 | -3% | -$6,835 | |||||
| D | 2026-02-23 | BDSX | Biodesix Inc | Vazquez Chris | Chief Accounting Officer | S - Sale+OE | $12.78 | -211 | 1,586 | -12% | -$2,696 | |||||
| D | 2026-02-23 | BDSX | Biodesix Inc | Hutton Scott | Pres, CEO | S - Sale+OE | $12.78 | -1,490 | 48,767 | -3% | -$19,036 | |||||
2026-02-19 | LH | Labcorp Holdings Inc. | Wilkinson Peter J | SVP, Chief Accounting Officer | S - Sale | $277.94 | -666 | 1,852 | -26% | -$185,108 | ||||||
| D | 2026-02-19 | DGX | Quest Diagnostics Inc | Plewman Patrick | SVP for Diagnostic Services | S - Sale+OE | $204.83 | -958 | 15,838 | -6% | -$196,227 | |||||
| D | 2026-02-19 | DGX | Quest Diagnostics Inc | Prevoznik Michael E | SVP, GC | S - Sale+OE | $204.83 | -1,111 | 44,109 | -2% | -$227,566 | |||||
| D | 2026-02-19 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP, Regional Businesses | S - Sale+OE | $204.83 | -1,433 | 72,905 | -2% | -$293,521 | |||||
| D | 2026-02-13 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP, Regional Businesses | S - Sale+OE | $206.15 | -26,165 | 72,571 | -26% | -$5,393,815 | |||||
| D | 2026-02-11 | LH | Labcorp Holdings Inc. | Schechter Adam H | Pres, CEO | S - Sale+OE | $284.38 | -5,273 | 89,478 | -6% | -$1,499,536 | |||||
| D | 2026-02-12 | LH | Labcorp Holdings Inc. | Meltzer Jonathan C | EVP, Operations | S - Sale+OE | $290.42 | -87 | 2,782 | -3% | -$25,267 | |||||
| D | 2026-02-10 | DGX | Quest Diagnostics Inc | Plewman Patrick | SVP for Diagnostic Services | S - Sale+OE | $204.00 | -5,662 | 15,381 | -27% | -$1,155,048 | |||||
| D | 2026-02-10 | LH | Labcorp Holdings Inc. | Meltzer Jonathan C | EVP, Operations | S - Sale+OE | $276.79 | -91 | 2,696 | -3% | -$25,188 | |||||
| D | 2026-02-10 | FTRE | Fortrea Holdings Inc. | Morais Mark A. | COO | S - Sale+OE | $13.88 | -1,179 | 62,677 | -2% | -$16,365 | |||||
| D | 2026-02-10 | FTRE | Fortrea Holdings Inc. | McConnell Jill G. | CFO | S - Sale+OE | $13.88 | -881 | 59,574 | -1% | -$12,229 | |||||
| D | 2026-02-10 | BDSX | Biodesix Inc | O'Kane Kieran | Chief Commercial Officer | S - Sale+OE | $10.08 | -584 | 8,885 | -6% | -$5,889 | |||||
| D | 2026-02-10 | BDSX | Biodesix Inc | Vazquez Chris | Chief Accounting Officer | S - Sale+OE | $10.08 | -101 | 1,234 | -8% | -$1,018 | |||||
| D | 2026-02-10 | BDSX | Biodesix Inc | Hutton Scott | Pres, CEO | S - Sale+OE | $10.08 | -3,559 | 45,413 | -7% | -$35,889 | |||||
| D | 2026-02-10 | BDSX | Biodesix Inc | Cowie Robin Harper | CFO, Sec'y, Treasurer | S - Sale+OE | $10.08 | -941 | 15,297 | -6% | -$9,489 | |||||
| D | 2026-02-10 | BDSX | Biodesix Inc | Pestano Gary Anthony | Chief Development Officer | S - Sale+OE | $10.08 | -540 | 9,387 | -5% | -$5,445 | |||||
| D | 2026-02-09 | LH | Labcorp Holdings Inc. | Meltzer Jonathan C | EVP, Operations | S - Sale+OE | $275.53 | -88 | 2,787 | -3% | -$24,247 | |||||
| M | 2026-02-03 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $39.52 | -4,017 | 345,070 | -1% | -$158,757 | |||||
| M | 2026-02-02 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $231.20 | -4,639 | 137,847 | -3% | -$1,072,538 | |||||
| M | 2026-02-02 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $230.72 | -90,024 | 123,156 | -42% | -$20,770,419 | |||||
2026-02-03 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $227.83 | -6,939 | 52,120 | -12% | -$1,580,926 | ||||||
2026-02-03 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $231.02 | -3,594 | 178,081 | -2% | -$830,279 | ||||||
2026-02-03 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $230.77 | -435 | 306,725 | 0% | -$100,384 | ||||||
2026-02-03 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $230.77 | -1,334 | 223,813 | -1% | -$307,845 | ||||||
2026-02-03 | CDNA | Caredx, Inc. | Novack Jeffrey Adam | Secretary, GC | S - Sale | $20.56 | -4,441 | 125,364 | -3% | -$91,286 | ||||||
| M | 2026-01-27 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $238.78 | -5,970 | 213,180 | -3% | -$1,425,506 | |||||
| M | 2026-01-27 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $235.38 | -5,064 | 59,059 | -8% | -$1,191,953 | |||||
| M | 2026-01-27 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $239.39 | -482 | 307,160 | 0% | -$115,388 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |